Abivax announces trading resumption of its ordinary shares on Euronext Paris
Abivax (Euronext Paris: ABVX) announced that trading of its ordinary shares on Euronext Paris will resume on July 1, 2026 at 3:30 p.m. CEST.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Abivax (Euronext Paris: ABVX) announced that trading of its ordinary shares on Euronext Paris will resume on July 1, 2026 at 3:30 p.m. CEST.
Trading was halted at the Company’s request from 9:00 a.m. CEST in connection with allocation confirmation and pricing of its US ADS public offering.
Details
News Market Reaction – ABVX
On Jul 1, the day this news came out, ABVX closed 0.53% below the previous close.
Data tracked by StockTitan Argus for the Jul 1 session.
Key Figures
- Trading halt time
- 9:00 a.m. CEST
- Start of trading halt on July 1, 2026 for ADS offering allocations
- Trading resumption time
- 3:30 p.m. CEST
- Resumption of ordinary share trading on Euronext Paris
- Announcement time
- 2:50 p.m. CEST
- Time of press release announcing trading resumption
- Nominal value per share
- €0.01 per share
- Ordinary share nominal value referenced in ADS public offering
- ADS-to-share ratio
- 1 ADS = 1 ordinary share
- Each American Depositary Share represents one ordinary share
Historical Context
-
Strong ABTECT Maintenance Part 2 results and NDA timing for obefazimod in UC.
-
Landmark Phase 3 ABTECT maintenance results with favorable efficacy and safety profile.
-
Q1 2026 results plus three‑year obefazimod extension data and extended cash runway.
-
Annual general meeting with all board‑proposed resolutions approved by shareholders.
-
Royalty certificate repurchase and $45M ADS offering improving capital structure and liquidity.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
public offering financial
regulated market regulatory
nominal value financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Abivax announces trading resumption of its ordinary shares on Euronext Paris
PARIS, France, July 1, 2026 – 02:50 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announced the trading resumption of its ordinary shares on the regulated market of Euronext Paris as from 3:30 p.m. CEST.
Trading of the ordinary shares of the Company was halted at the request of the Company on July 1, 2026 from 9:00 a.m. CEST in the context of the previously announced public offering by the Company of its American Depositary Shares, each representing one ordinary share,
***
About Abivax
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.
Contacts:
| Abivax Investor Relations Patrick Malloy patrick.malloy@abivax.com +1 847 987 4878 |
***
Disclaimer
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company, nor shall there be any sale of such securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Attachment
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.